Ovid Therapeutics Announces Significant Pipeline Progress, Indication Expansion, and Strong Financial Position in FY2025 Results

Key Highlights for Shareholders

• Positive Clinical Data for OV329: The 7 mg dose of OV329, Ovid’s next-generation GABA-aminotransferase (GABA-AT) inhibitor, demonstrated a favorable safety and tolerability profile in Phase 1 studies. This strengthens OV329’s potential as a “best-in-category” option for drug-resistant epilepsies.
• Indication Expansion for OV329: Ovid is expanding the development of OV329 into two highly strategic and underserved indications: tuberous sclerosis complex (TSC)-associated seizures and infantile spasms (IS), supported by a \$60 million private placement.
• New Program OV4071 Cleared for Clinical Trials: OV4071, a first-in-class, oral KCC2 direct activator, received Human Research Ethics Committee approval and Clinical Trial Notification acknowledgment from the Australian Therapeutic Goods Administration, enabling the initiation of a Phase 1 study.
• Upcoming Investor Events: The company will host a KCC2-focused R&D Day on April 14, 2026, and a business update call for investors.
• Strong Financial Position: Ovid ended 2025 with \$90.4 million in cash, cash equivalents, and marketable securities, sufficient to fund operations and key clinical programs into late 2028, with potential extension into 2029 upon full execution of warrants.
• Potential Share Price Catalysts: If all Series A Warrants are exercised, Ovid could receive up to an additional \$53.9 million, potentially extending its cash runway further and supporting accelerated clinical development.

In-Depth Pipeline Updates

OV329: Advancing with Strong Safety and Efficacy Signals

The latest data from the 7 mg cohort in the Phase 1 study of OV329 showed no treatment-related adverse events, with all 19 unrelated adverse events being mild and transient. Across all dose levels (3 mg, 5 mg, 7 mg), OV329 has demonstrated robust safety and tolerability, with no cases of serious adverse events. Importantly, OV329 displayed strong, statistically significant cortical inhibition activity and increased GABA levels, matching or exceeding the effects of therapeutic doses of vigabatrin (a first-generation GABA-AT inhibitor) but without the significant retinal accumulation and associated safety concerns seen with vigabatrin.

Ovid plans to initiate:

• An open-label photo paroxysmal response study to evaluate the anti-seizure effect of OV329 in Q3 2026.
• A Phase 2 randomized, placebo-controlled trial for treatment-resistant focal onset seizures (FOS) in Q2 2026.

The company is also developing a pediatric-specific formulation of OV329 for infant and child use.

Indication Expansion: TSC and Infantile Spasms

Ovid will expand OV329 into TSC-associated seizures and IS, both of which are rare, severe pediatric epileptic disorders with significant unmet need. The company aims to initiate a proof-of-concept safety and signal-finding study in TSC in Q4 2026, and a similar study in IS in 2027. These programs will be advanced in parallel with the FOS indication and may support an accelerated development pathway.

KCC2 Portfolio: First-in-Class Progress and Expansion

• OV4071 (Oral KCC2 Direct Activator): Cleared to begin Phase 1 trials in Australia in Q2 2026. OV4071 is initially focused on psychosis associated with Parkinson’s disease and Lewy body dementia, with plans for a ketamine challenge study in mid-2026. Ovid believes OV4071 could have broader applications in schizophrenia and psychosis related to Alzheimer’s disease.
• OV350 (IV KCC2 Direct Activator): Positive Phase 1 data reported, demonstrating clinical validation of direct KCC2 activation in humans. No treatment-related serious adverse events, and PK results as predicted.
• Pipeline Expansion: Ovid continues developing additional oral and injectable KCC2 activators for a broad range of CNS disorders, supporting a sustainable, innovation-driven pipeline.

The company will showcase its KCC2 portfolio at its R&D Day on April 14, 2026.

Financial Highlights and Capital Structure Updates

• Cash Position: \$90.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Private Placement: On March 17, 2026, Ovid entered into a Securities Purchase Agreement to issue 19.15 million shares and 10.7 million pre-funded warrants at \$2.01 and \$2.009 per share/warrant, respectively, raising \$60 million in gross proceeds (pre-fees and expenses) to support OV329’s expanded development.
• Warrant Exercise Opportunity: HREC approval for OV4071 triggers a 30-day window (expiring April 17, 2026) for investors to exercise Series A Warrants, with potential proceeds of \$53.9 million.
• Revenue and Profitability:
  • Q4 2025 revenue was \$0.7 million; full-year 2025 revenue was \$7.3 million, including a one-time \$7.0 million payment related to future royalties.
  • Research & development expenses for FY2025: \$25.6 million (down from \$36.8 million in FY2024 due to prior restructuring).
  • General & administrative expenses for FY2025: \$24.1 million (down from \$25.7 million in FY2024).
  • Net income for Q4 2025: \$9.7 million, driven by a \$21 million gain on adjustment in the fair value of a long-term equity investment. For FY2025, net loss was \$17.4 million, improved from \$26.4 million in 2024.
• Balance Sheet: Total assets of \$150.9 million and total stockholders’ equity of \$130.7 million as of December 31, 2025.

Key Upcoming Catalysts and Events

• Phase 2 dose confirmatory study for OV329 in drug-resistant epilepsies (Q2 2026 start)
• Initiation and completion of an open-label, patient proof-of-concept photo paroxysmal response study (Q3 2026 start)
• Potential initiation and completion of a proof-of-concept trial for OV4071 (Q2 2026 start)
• Initiation and results of a ketamine challenge study for OV4071 (mid-2026 start)
• Potential initiation and completion of Phase 1b studies for OV4071 in psychosis associated with Parkinson’s disease, Lewy body dementia, and schizophrenia
• KCC2-focused R&D Day (April 14, 2026)
• Business update call and webcast for investors (March 18, 2026, with webcast replay available for 90 days)

Why This Matters to Shareholders

• Multiple Near-Term Milestones: Ovid is approaching several pivotal clinical milestones within the next 18-24 months, each with the potential to significantly impact share value.
• Expanded Pipeline and Indications: The expansion of OV329 into TSC and IS, as well as the advancement of OV4071 and the broader KCC2 portfolio, reflect Ovid’s strategic commitment to addressing high-value, high-need CNS indications.
• Strong Cash and Capital Infusion Potential: With the current cash position, additional proceeds from the private placement, and potential warrant exercises, Ovid is well-capitalized to deliver on its pipeline promises and weather market volatility.
• Shareholder Value Creation: Each successful clinical milestone, regulatory clearance, and positive data readout may serve as a catalyst for share price appreciation, given the significant unmet need and market opportunity in the CNS/epilepsy space.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as described in Ovid Therapeutics’ filings with the SEC. Investors should review all company disclosures and consult their financial advisors before making investment decisions.

View Ovid Therapeutics Inc. Historical chart here